UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000040506
Receipt No. R000046239
Scientific Title Cancer gene panel of plasma DNA in patients with solid tumor
Date of disclosure of the study information 2020/05/26
Last modified on 2020/05/25 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Cancer gene panel of plasma DNA in patients with solid tumor
Acronym Cancer gene panel of plasma DNA in patients with solid tumor
Scientific Title Cancer gene panel of plasma DNA in patients with solid tumor
Scientific Title:Acronym Cancer gene panel of plasma DNA in patients with solid tumor
Region
Japan

Condition
Condition Solid tumor
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To evaluate the gene analysis of plasma DNA by NGS in patients with metastatic solid tumor
Basic objectives2 Bio-equivalence
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Detection rate of somatic gene alterations in plasma DNA
Key secondary outcomes Detection rate of somatic gene alterations in plasma DNA by cancer type.
Detection rate of somatic gene alterations in plasma DNA by gene.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
110 years-old >=
Gender Male and Female
Key inclusion criteria 1) Patinets with metastatic solic tumor
2) Age >= 20 years old
3) Patients with tumor harboring gene alteration
4) Written informed consent
Key exclusion criteria None
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Kenichi
Middle name
Last name Urakami
Organization Shizuoka Cancer Center Research Institute
Division name Cancer Diagnostics Research Division
Zip code 411-8777
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun
TEL 0559895222
Email k.urakami@scchr.jp

Public contact
Name of contact person
1st name Hirotsugu
Middle name
Last name Kenmotsu
Organization Shizuoka Cancer Center
Division name Division of Genetic Medicine Promotion
Zip code 411-8777
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun
TEL 0559895222
Homepage URL
Email h.kenmotsu@scchr.jp

Sponsor
Institute Shizuoka Cancer Center
Institute
Department

Funding Source
Organization Shizuoka Cancer Center
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Shizuoka Cancer Center IRB
Address 1007 Shimonagakubo, Nagaizumi-cho
Tel 0559895222
Email rinsho_office@scchr.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 05 Month 26 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2020 Year 05 Month 13 Day
Date of IRB
2020 Year 05 Month 22 Day
Anticipated trial start date
2020 Year 05 Month 27 Day
Last follow-up date
2022 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information 20 mL blood sample will be obtained from patiets emrolled into this study.

Management information
Registered date
2020 Year 05 Month 25 Day
Last modified on
2020 Year 05 Month 25 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046239